| 发明名称 | Sustained release dosage form | ||
| 摘要 | The novel sustained release dosage form comprising an active agent and a combination of a non-swelling pH dependent release retardant and a non swelling pH independent release retardant polymer which provides pH-independent drug release for a considerable period of time after administration. | ||
| 申请公布号 | US8920837(B2) | 申请公布日期 | 2014.12.30 |
| 申请号 | US200611994385 | 申请日期 | 2006.07.03 |
| 申请人 | Rubicon Research Private Limited | 发明人 | Pilgaonkar Pratibha S.;Rustomjee Maharukh T.;Gandhi Anilkumar S.;Jain Paras R.;Kelkar Atul A. |
| 分类号 | A61K9/22;A61K9/36;A61K31/135;A61K31/155;A61K31/34;A61K31/445;A61K31/40;A61K9/20 | 主分类号 | A61K9/22 |
| 代理机构 | Seyfarth Shaw, LLP | 代理人 | Seyfarth Shaw, LLP ;Acharya Nigamnarayan;Upadhye Shashank |
| 主权项 | 1. A sustained-release oral dosage form comprising, a. therapeutically effective amount of a pharmacologically active ingredient having aqueous solubility of greater than 1 mg/ml, b. at least one non-swelling pH dependent, release retardant in an amount from about 10 to about 90% by weight of the total composition, and c. at least one non-swelling pH independent, release-retardant in an amount from about 10 to about 90% by weight of the total composition, wherein the dosage form provides pH independent drug release for a considerable period of time after administration, and the dosage form is a matrix dosage form. | ||
| 地址 | Mumbai IN | ||